Literature DB >> 18021481

Can core biopsy be used instead of surgical biopsy in the diagnosis and prognostic factor analysis of breast carcinoma?

Aysegul Ozdemir1, Nuray Kadioglu Voyvoda, Serap Gultekin, Isil Tuncbilek, Ayse Dursun, Deniz Yamac.   

Abstract

PURPOSE: The aim of this article was to investigate the efficacy of ultrasonography-guided core needle biopsy and prognostic factor analysis of breast cancer to plan overall treatment strategy. PATIENTS AND METHODS: A consecutive series of nonpalpable and palpable breast cancers constituted our study group (n= 201 lesions; mean size, 20.4 mm) Mean number of core samples was 3.4. Malignant lesions diagnosed with core biopsy underwent therapeutic surgical excision. Core biopsy and surgical excisions were compared for histologic type, grade, estrogen receptors (ERs), progesterone receptors (PgRs), and c-erbB2 levels. Cutoff values for ER, PgR, and c-erbB2 affecting the management strategy were selected as 10%, 10%, and 50%, respectively.
RESULTS: Eighty-five lesions (42.3%) were malignant in core biopsy (mean size, 18.4 mm). Among these, 11 were inoperable and 13 were surgically excised at other institutions. In 61 lesions, core and surgical excision specimens were evaluated in the same institution (mean tumor size, 18.6 mm; range 6-60 mm). Concordance between the 2 biopsy methods was 85.2% (52 of 61) for histologic type of tumor, 68.8% (33 of 48) for tumor grade, 90% (27 of 30) for ER, 86.7% (26 of 30) for PgR, and 79.3% (23 of 29) for c-erbB2 levels. Appropriate site selection for sampling was indicated to be of paramount importance, especially in determining reliable ER, PgR, and c-erbB2 levels.
CONCLUSION: Core needle biopsy of breast cancer is equally effective compared with surgical biopsy and can be used in overall treatment planning. However, appropriate site selection for sampling should be guaranteed using ultrasonographic guidance.

Entities:  

Mesh:

Year:  2007        PMID: 18021481     DOI: 10.3816/cbc.2007.n.041

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  6 in total

1.  Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases.

Authors:  Jie Chen; Zu Wang; Qing Lv; Zhenggui Du; Qiuwen Tan; Di Zhang; Bingjun Xiong; Helin Zeng; Juxiang Gou
Journal:  Pathol Oncol Res       Date:  2017-01-10       Impact factor: 3.201

2.  Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.

Authors:  Aravind Barathi Asogan; Ga Sze Hong; Subash Kumar Arni Prabhakaran
Journal:  Singapore Med J       Date:  2016-03-31       Impact factor: 1.858

3.  Reliability of receptor assessment on core needle biopsy in breast cancer patients.

Authors:  S C Seferina; M Nap; F van den Berkmortel; J Wals; A C Voogd; V C G Tjan-Heijnen
Journal:  Tumour Biol       Date:  2012-12-27

4.  Cryotherapy for breast cancer: a feasibility study without excision.

Authors:  Peter J Littrup; Bassel Jallad; Priti Chandiwala-Mody; Monica D'Agostini; Barbara A Adam; David Bouwman
Journal:  J Vasc Interv Radiol       Date:  2009-10       Impact factor: 3.464

5.  Gradual adoption of needle biopsy for breast lesions in a rural state.

Authors:  Serena Murphy; Yi-Chuan Yu; Colleen Kerrigan; Brian Sprague; Michelle Sowden
Journal:  Cancer Med       Date:  2021-11-09       Impact factor: 4.452

6.  Assessment of Breast Specimens With or Without Calcifications in Diagnosing Malignant and Atypia for Mammographic Breast Microcalcifications Without Mass: A STARD-Compliant Diagnostic Accuracy Article.

Authors:  Yun-Chung Cheung; Yu-Hsiang Juan; Shir-Hwa Ueng; Yung-Feng Lo; Pei-Chin Huang; Yu-Ching Lin; Shin-Cheh Chen
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.